Neogenomics Stock Performance
| NEO Stock | USD 12.50 0.19 1.54% |
On a scale of 0 to 100, NeoGenomics holds a performance score of 10. The company secures a Beta (Market Risk) of 0.83, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, NeoGenomics' returns are expected to increase less than the market. However, during the bear market, the loss of holding NeoGenomics is expected to be smaller as well. Please check NeoGenomics' expected short fall, and the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether NeoGenomics' current price movements will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in NeoGenomics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating technical and fundamental indicators, NeoGenomics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.54 | Five Day Return 0.81 | Year To Date Return 6.29 | Ten Year Return 96.23 | All Time Return 2.8 K |
Last Split Factor 1:100 | Last Split Date 2003-04-16 |
1 | NeoGenomics price target raised by 1 at Piper Sandler, heres why NEO | 11/10/2025 |
2 | Disposition of 8776 shares by Warren Stone of NeoGenomics subject to Rule 16b-3 | 12/01/2025 |
3 | Disposition of 11938 shares by Sherman Jeffrey Scott of NeoGenomics subject to Rule 16b-3 | 12/05/2025 |
4 | 3 Stocks Under 50 We Steer Clear Of | 12/17/2025 |
5 | Insider Trading | 12/31/2025 |
6 | NEO Battery Achieves Official Vendor Status with Asian Fortune Global 500 Automotive OEM | 01/05/2026 |
7 | atom11 Launches Neo, Award-Winning Amazon Ads Copilot for Amazon Sellers | 01/06/2026 |
8 | NeoGenomics sees Q4 revenue of about 190M | 01/12/2026 |
9 | Disposition of 15145 shares by Alicia Olivo of NeoGenomics subject to Rule 16b-3 | 01/13/2026 |
10 | Neo Trading 8.1 percent Lower Over Last Week | 01/20/2026 |
11 | Dont Ignore The Insider Selling In NeoGenomics | 01/23/2026 |
12 | SpoonOS launches Web3 skills marketplace for AI agents | 01/29/2026 |
| Begin Period Cash Flow | 342.5 M | |
| Total Cashflows From Investing Activities | 12.9 M |
NeoGenomics | Build AI portfolio with NeoGenomics Stock |
NeoGenomics Relative Risk vs. Return Landscape
If you would invest 1,040 in NeoGenomics on November 6, 2025 and sell it today you would earn a total of 210.00 from holding NeoGenomics or generate 20.19% return on investment over 90 days. NeoGenomics is generating 0.3373% of daily returns assuming volatility of 2.4982% on return distribution over 90 days investment horizon. In other words, 22% of stocks are less volatile than NeoGenomics, and above 94% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
NeoGenomics Target Price Odds to finish over Current Price
The tendency of NeoGenomics Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 12.50 | 90 days | 12.50 | about 22.06 |
Based on a normal probability distribution, the odds of NeoGenomics to move above the current price in 90 days from now is about 22.06 (This NeoGenomics probability density function shows the probability of NeoGenomics Stock to fall within a particular range of prices over 90 days) .
NeoGenomics Price Density |
| Price |
Predictive Modules for NeoGenomics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as NeoGenomics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of NeoGenomics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
NeoGenomics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. NeoGenomics is not an exception. The market had few large corrections towards the NeoGenomics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold NeoGenomics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of NeoGenomics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.28 | |
β | Beta against Dow Jones | 0.83 | |
σ | Overall volatility | 1.00 | |
Ir | Information ratio | 0.11 |
NeoGenomics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of NeoGenomics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for NeoGenomics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the last year's revenue of 660.57 M. Reported Net Loss for the year was (78.73 M) with profit before taxes, overhead, and interest of 307.81 M. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from finbold.com: SpoonOS launches Web3 skills marketplace for AI agents |
NeoGenomics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of NeoGenomics Stock often depends not only on the future outlook of the current and potential NeoGenomics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. NeoGenomics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 25.3 M | |
| Cash And Short Term Investments | 386.8 M |
NeoGenomics Fundamentals Growth
NeoGenomics Stock prices reflect investors' perceptions of the future prospects and financial health of NeoGenomics, and NeoGenomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NeoGenomics Stock performance.
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0303 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 1.84 B | ||||
| Shares Outstanding | 129.39 M | ||||
| Price To Earning | 272.37 X | ||||
| Price To Book | 1.90 X | ||||
| Price To Sales | 2.28 X | ||||
| Revenue | 660.57 M | ||||
| Gross Profit | 307.81 M | ||||
| EBITDA | (1.51 M) | ||||
| Net Income | (78.73 M) | ||||
| Cash And Equivalents | 465.95 M | ||||
| Cash Per Share | 3.70 X | ||||
| Total Debt | 605.33 M | ||||
| Debt To Equity | 0.59 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 6.50 X | ||||
| Cash Flow From Operations | 7.02 M | ||||
| Earnings Per Share | (0.89) X | ||||
| Market Capitalization | 1.62 B | ||||
| Total Asset | 1.64 B | ||||
| Retained Earnings | (325.78 M) | ||||
| Working Capital | 294.78 M | ||||
| Current Asset | 82.36 M | ||||
| Current Liabilities | 40.06 M | ||||
About NeoGenomics Performance
By examining NeoGenomics' fundamental ratios, stakeholders can obtain critical insights into NeoGenomics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that NeoGenomics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 23.72 | 17.74 | |
| Return On Tangible Assets | (0.09) | (0.10) | |
| Return On Capital Employed | (0.08) | (0.08) | |
| Return On Assets | (0.04) | (0.05) | |
| Return On Equity | (0.10) | (0.10) |
Things to note about NeoGenomics performance evaluation
Checking the ongoing alerts about NeoGenomics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NeoGenomics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the last year's revenue of 660.57 M. Reported Net Loss for the year was (78.73 M) with profit before taxes, overhead, and interest of 307.81 M. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from finbold.com: SpoonOS launches Web3 skills marketplace for AI agents |
- Analyzing NeoGenomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NeoGenomics' stock is overvalued or undervalued compared to its peers.
- Examining NeoGenomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NeoGenomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of NeoGenomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NeoGenomics' stock. These opinions can provide insight into NeoGenomics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Will Health Care Providers & Services sector continue expanding? Could NeoGenomics diversify its offerings? Factors like these will boost the valuation of NeoGenomics. Anticipated expansion of NeoGenomics directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every NeoGenomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.306 | Earnings Share (0.89) | Revenue Per Share | Quarterly Revenue Growth 0.119 | Return On Assets |
Investors evaluate NeoGenomics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating NeoGenomics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause NeoGenomics' market price to deviate significantly from intrinsic value.
It's important to distinguish between NeoGenomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NeoGenomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, NeoGenomics' market price signifies the transaction level at which participants voluntarily complete trades.